Capital Fund Management (CFM)
AMLX icon

Capital Fund Management (CFM)’s Amylyx Pharmaceuticals AMLX Stock Holding History

Capital Fund Management (CFM)’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,281
Closed -$265K – 1912
2023
Q2 		$265K Buy
+12,281
New +$332K ﹤0.01% 1633

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Capital Fund Management (CFM)'s AMLX Position: Q3 2023 in Review

Capital Fund Management (CFM) sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2023, closing a stake of 12,281 shares — an estimated $265K sold.

Capital Fund Management (CFM) first reported a position in AMLX in Q2 2023 and held it in 1 quarter. The position peaked at $265K in Q2 2023. 170 funds tracked by Wall St. Rank hold AMLX as of Q3 2023.

  • Capital Fund Management (CFM) reported no remaining Amylyx Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Capital Fund Management (CFM) sold 12,281 Amylyx Pharmaceuticals shares in Q3 2023, an estimated $265K.
  • Capital Fund Management (CFM) first reported a position in Amylyx Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Capital Fund Management (CFM)'s Amylyx Pharmaceuticals position peaked at $265K in Q2 2023.
  • 170 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2023.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2023, filed 14 Nov 2023.